Opus Genetics Inc. (IRD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Opus Genetics Inc. (IRD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.16

-0.05 (-4.13%)

At close: Jan 14, 2025, 3:59 PM

1.16

0.04%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.15
Market Cap	36.60M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.09
PE Ratio (ttm)	-1.06
Forward PE	n/a
Analyst	Buy

Ask	1.34
Volume	116,063
Avg. Volume (20D)	234,839
Open	1.23
Previous Close	1.21
Day's Range	1.15 - 1.31
52-Week Range	0.81 - 3.04
Beta	undefined

About IRD

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a smal...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 19, 2015

Employees 14

Stock Exchange NASDAQ

Ticker Symbol IRD

Website https://opusgtx.com

Analyst Forecast

According to 1 analyst ratings, the average rating for IRD stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 589.95% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago · Source

+18.93%

Opus Genetics shares are trading higher after the ... Unlock content with Pro Subscription

News

2 months ago · zacks.com

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to earnings of $0.25 per share a year ago.